Sona Nanotech Inc (TSE:SONA) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Sona Nanotech Inc. announced promising results from its preclinical study using Targeted Hyperthermia Therapy to treat colorectal cancer, which showed enhanced response rates when combined with standard immunotherapy. The study revealed that tumors in mice were significantly reduced, with half of them eliminated, demonstrating the potential of the therapy to convert resistant cancers into responsive ones.
For further insights into TSE:SONA stock, check out TipRanks’ Stock Analysis page.